STING activation triggers robust type-I IFN secretion from dendritic cells and other stromal cells, stimulates the cross-priming of tumor neoantigens to CD8+ T cells, and finally induces anti-tumor adaptive immunity within the TME [18,81,82]. Here, STING1 is linked to neoplasm.